Want to see DCOY full AI Analyst Report?
Top Page
Decoy Therapeutics
(NASDAQ:DCOY)
Select Model
Select Model
Rating:43Neutral
Price Target:
$3.00
▲(1.01% Upside)
Action:Reiterated
Date:08/18/26
The score is driven primarily by weak financial performance (no revenue, ongoing losses and cash burn, and declining equity) and bearish technicals (price below all key moving averages with negative MACD). A modest offset comes from the PIPE financing improving near-term liquidity, but valuation metrics are not supportive due to continued unprofitability and no dividend.
Positive Factors
Debt-free balance sheet
The absence of material debt reduces solvency pressure and interest obligations, giving Decoy greater flexibility to direct limited capital toward research and clinical development rather than debt servicing.
Negative Factors
Pre-revenue business model
Decoy has no commercial revenue base to fund operations, leaving future progress dependent on clinical success, external financing, and eventual product commercialization rather than recurring operating cash inflows.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
The absence of material debt reduces solvency pressure and interest obligations, giving Decoy greater flexibility to direct limited capital toward research and clinical development rather than debt servicing.
Read all positive factors
Decoy Therapeutics (DCOY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.90M
Dividend YieldN/A
Average Volume (3M)356.88K
Price to Earnings (P/E)―
Beta (1Y)2.13
Revenue GrowthN/A
EPS Growth91.92%
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding655,185
10 Day Avg. Volume434,140
30 Day Avg. Volume356,875
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-0.78
Enterprise Value/Market Cap-2.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.55
Enterprise Value/Ebitda0.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Decoy Therapeutics Business Overview & Revenue Model
Company Description
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthe...
Decoy Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -8.52M | -8.52M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -14.44M | -12.51M | -5.57M | -12.53M | -22.97M | -12.75M |
| Net Income | -14.45M | -12.52M | -5.58M | -12.54M | -31.61M | -12.77M |
Balance Sheet | ||||||
| Total Assets | 9.00M | 11.06M | 3.02M | 6.59M | 14.65M | 40.83M |
| Cash, Cash Equivalents and Short-Term Investments | 8.29M | 10.71M | 2.43M | 5.90M | 12.11M | 29.21M |
| Total Debt | 0.00 | 0.00 | 221.87K | 289.64K | 0.00 | 0.00 |
| Total Liabilities | 4.68M | 5.17M | 1.51M | 1.30M | 4.27M | 2.11M |
| Stockholders Equity | 4.32M | 5.89M | 1.51M | 5.29M | 10.38M | 38.72M |
Cash Flow | ||||||
| Free Cash Flow | -8.37M | -4.83M | -4.53M | -12.85M | -19.10M | -10.20M |
| Operating Cash Flow | -8.32M | -4.83M | -4.53M | -12.85M | -17.60M | -10.20M |
| Investing Cash Flow | 722.31K | 764.74K | 0.00 | 0.00 | -1.50M | 0.00 |
| Financing Cash Flow | 15.10M | 12.34M | 1.06M | 6.64M | 1.99M | 28.30M |
Decoy Therapeutics Technical Analysis
Negative
2.97
Price Trends
4.91
Negative
5.50
Negative
7.23
Negative
Market Momentum
-0.53
Negative
28.44
Positive
10.83
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DCOY, the sentiment is Negative. The current price of 2.97 is below the 20-day moving average (MA) of 3.57, below the 50-day MA of 4.91, and below the 200-day MA of 7.23, indicating a bearish trend. The MACD of -0.53 indicates Negative momentum. The RSI at 28.44 is Positive, neither overbought nor oversold. The STOCH value of 10.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DCOY.
Decoy Therapeutics Risk Analysis
Decoy Therapeutics disclosed 47 risk factors in its most recent earnings report. Decoy Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Decoy Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $1.90M | -0.10 | -395.42% | ― | ― | 91.92% | |
| ― | $2.37M | -0.15 | -177.32% | ― | ― | 86.26% | |
52 Neutral | $3.41M | -0.02 | -438.03% | ― | ― | 53.95% | |
42 Neutral | $4.73M | -0.04 | -151.28% | ― | ― | 98.95% | |
39 Underperform | $12.66M | -0.04 | 3114.17% | ― | ― | 85.06% |
* Healthcare Sector Average
DCOY
Decoy Therapeutics
2.90
-66.22
-95.80%
OGEN
Oragenics
0.52
-0.53
-50.10%
MBRX
Moleculin Biotech
0.65
-9.16
-93.38%
PPCB
Propanc Biopharma
1.35
-74.15
-98.21%
GNPX
Genprex
3.67
-176.73
-97.97%
CLDI
Calidi Biotherapeutics
1.32
-25.08
-95.00%
Decoy Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Decoy Therapeutics Secures PIPE Financing to Advance Trials
Positive
Jun 29, 2026
On June 26, 2026, Decoy Therapeutics Inc. entered into a private investment in public equity financing with a single healthcare-focused institutional investor, structured around an at-the-market-priced securities purchase agreement. The deal is ex...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.